Topical ranibizumab as a treatment of corneal neovascularization.
Topical ranibizumab as a treatment of corneal neovascularization.
复制标题
DOI：
10.1097/ico.0b013e3182775f8d
复制
发表时间：
2013-07
期刊：
影响因子：
2.8
通讯作者：
Dana R
中科院分区：
文献类型：
--
作者：
Ferrari G;Dastjerdi MH;Okanobo A;Cheng SF;Amparo F;Nallasamy N;Dana R
检查局部雷珠单抗对临床稳定的角膜新生血管（NV）的影响。这是一项前瞻性、开放标签、单中心、非对照、非比较性研究。9例角膜NV患者的10只眼接受了局部雷珠单抗（1%），每日4次，持续3周，随访16周。主要的角膜新生血管结局指标为：新生血管面积（NA），即角膜新生血管所占的面积;血管口径（VC），即角膜新生血管的平均直径;以及浸润面积（IA），即血管覆盖的角膜总面积的分数。本研究在马萨诸塞州眼耳医院（Boston，MA，USA）进行。治疗后观察到NA（55.3%，P<0.001）和VC（59%，P<0.001）的统计学显著降低，持续至16周，持续改善至16周。IA未观察到显著降低（12.3%，P=0.49）。视力或眼内压无统计学显著变化。未观察到归因于治疗的不良事件。局部应用雷珠单抗可有效降低角膜NV的严重程度，主要是通过降低VC而不是IA。
To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). This was a prospective, open-label, monocentric, uncontrolled, non-comparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up of 16 weeks. The main corneal neovascularization outcome measures were: neovascular area (NA), the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA, USA. Statistically significant decreases in NA (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P<0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P=0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.